相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1987
已完成
3
100.0%
暂无批准数据
- A comprehensive data analysis of the 340B Drug Discount Program found that utilization increases, not pharmaceutical price hikes, accounted for 100.7% of program growth from 2018 to 2024. - The 340B program has tripled in size over the past decade, reaching $148 billion in 2024 at list price, with a 24% year-over-year increase in 2023 alone. - Despite claims from 340B advocates that manufacturer price increases drive program growth, the study found utilization contributed 4.6 times more to growth than price increases. - The analysis challenges longstanding assertions from hospital advocacy groups and reveals significant implications for payers who must cover the spread between discounted acquisition costs and full reimbursement rates.
• Pharmacist Jay Holloway highlights single-tablet regimens and long-acting injectables like CABENUVA as key advancements improving HIV medication adherence and patient outcomes. • The PURPOSE trial, evaluating lenacapavir for PrEP, shows promise in providing more tools to meet diverse patient needs and preferences in HIV prevention. • Holloway emphasizes the importance of addressing health disparities and supporting the overall well-being of individuals living with HIV to improve medication adherence and outcomes. • Undetectable equals untransmissible (U=U) concept is crucial; individuals with undetectable viral loads cannot transmit HIV sexually, reducing stigma and promoting public health.
• Gilead Sciences will roll out Lenacapavir in 120 low-income countries via royalty-free licenses, offering a twice-yearly injectable for HIV prevention. • Clinical trials showed Lenacapavir's high efficacy in reducing HIV transmission, surpassing daily oral PrEP regimens, leading to early study halts for expedited approval. • Exclusion of middle- and high-income countries with high HIV rates, like Brazil and Mexico, has drawn criticism from advocacy groups. • UNAIDS welcomes Lenacapavir's expansion but urges broader access to ensure the medication reaches all who need it to combat the global HIV epidemic.
